Further subgroup analyses with respect to tumor stage, grade, and TP53 mutation status showed that the methylation level of the CAPG promoter decreased with higher tumor stages and was lowest in tumor grade 4, while the TP53 mutant group exhibited lower methylation levels than the TP53 non-mutant group (Figures 3B-D). The gene discussed is CAPG; the disease is neoplasm.